¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Active Transport, Cell Nucleus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • gracile nucleus
    ³ÎÆÇÇÙ
  • habenular nucleus
    °í»ßÇÙ
  • hyperchromatic nucleus
    °ú´Ù¿°»öÇÙ, °ú¿°»öÇÙ
  • hypoglossal nucleus
    Çô¹Ø½Å°æÇÙ, ¼³ÇϽŰæÇÙ
  • hypothalamic nucleus
    ½Ã»óÇϺÎÇÙ
  • inferior olivary nucleus
    ¾Æ·¡¿Ã¸®ºêÇÙ, ÇϿø®ºêÇÙ
  • infundibular nucleus
    ±ò¶§±âÇÙ, ´©µÎÇÙ
  • intermitotic nucleus
    ºÐ¿­»çÀ̱âÇÙ, ºÐ¿­°£±âÇÙ
  • interpeduncular nucleus
    ´ë³ú´Ù¸®»çÀÌÇÙ, °æ°£ÇÙ
  • interstitial nucleus
    »çÀÌÁúÇÙ, °£ÁúÇÙ
  • intralaminar reticular nucleus
    ¼¶À¯ÆÇ¼Ó±×¹°ÇÙ, ÆÇ³»¸Á»óÇÙ
  • lenticular nucleus
    ·»ÁîÇÙ
  • lentiform nucleus
    ·»ÁîÇÙ
  • lacrimal nucleus
    ´«¹°ºÐºñÇÙ, ´©ÇÙ
  • mitotic nucleus
    À¯»çºÐ¿­±âÇÙ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • target cell
    Ç¥Àû¼¼Æ÷
  • transitional cell
    ÀÌÇ༼Æ÷
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • cell line
    ¼¼Æ÷ÁÖ
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • emboliform nucleus
    ¸¶°³ÇÙ
  • facial nucleus
    ¾ó±¼½Å°æÇÙ
  • fastigial nucleus
    ²ÀÁöÇÙ
  • fertilization nucleus
    ¼öÁ¤ÇÙ
  • flat nucleus
    ÆíÆòÇÙ
  • free nucleus
    À¯¸®ÇÙ
  • fusiform nucleus
    ¹æÃßÇÙ
  • geniculate nucleus
    ¹«¸­ÇÙ
  • gigantocellular nucleus
    °Å´ë¼¼Æ÷ÇÙ
  • globose nucleus
    µÕ±ÙÇÙ
  • gracile nucleus
    ³ÎÆÇÇÙ
  • habenular nucleus
    °í»ßÇÙ
  • hyperchromatic nucleus
    °ú´Ù¿°»öÇÙ
  • hypoglossal nucleus
    Çô¹Ø½Å°æÇÙ
  • hypothalamic nucleus
    ½Ã»óÇϺÎÇÙ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • gray nucleus
    ȸ»öÇÙ(üéßäú·).
  • head of caudate nucleus
    ²¿¸®ÇÙ¸Ó¸®
  • herniated nucleus pulposus
    Å»Ãâ¼öÇÙ(¡­¼öÇÙ).
  • herniated nucleus pulposus
    ¼öÇÙ Å»ÃâÁõ(âÐú·÷­õóñø), Å»Ãâ ¼öÇÙ(¡­âÐú·).
  • herniation of nucleus pulposus
    ¼öÇÙ Å»ÃâÁõ(âÐú·÷­õóñø), Å»Ãâ ¼öÇÙ(÷­õóâÐú·), ¼öÇÙ Å»Ãâ(âÐú·÷­õó).
  • herniation of nucleus pulposus
    ¼öÇÙÅ»Ãâ(âÐú·÷­õó).
  • hilum of dentate nucleus
    Ä¡¾ÆÇÙ¹®
  • hilum of inferior olivary nucleus
    ¾Æ·¡¿Ã¸®ºêÇÙ¹®
  • hydrogen nucleus
    ¼ö¼ÒÇÙ
  • hypoglossal nucleus
    Çô¹Ø½Å°æÇÙ
  • inferior salivary nucleus
    ¾Æ·¡Ä§ºÐºñÇÙ, ÇÏŸ¾×ÇÙ(ù»öääûú·).
  • inferior salivary nucleus
    ÇÏŸ¾×ÇÙ
  • inferior salivatory nucleus
    ¾Æ·¡Ä§ºÐºñÇÙ
  • phrenic nucleus
    °¡·Î¸·½Å°æÇÙ
  • piriform nucleus
    Á¶·Õ¹ÚÇÙ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • supersonic transport
    ÃÊÀ½ÆÄ¼ö¼Û(¡­âÃáê).
  • symport= co- transport
    °øµ¿¿î¹Ý(ÍìÔÒê¡Úæ)
  • transcapillary transport
    ¸ð¼¼°ü¿î¹Ý (¡­ê¡Úæ)
  • transcapillary transport
    ¸ð¼¼°ü¿î¹Ý (¡­ê¡Úæ).
  • transmembrane transport
    ¸· Åë°ú À̵¿
  • transport defect
  • transport maxima
    ÃÖ´ëÀ̵¿Ä¡(õÌÓÞì¹ÔÑö·).
  • transport maximum
    ÃÖ´ëÀ̵¿Ä¡(õÌÓÞì¹ÔÑö·)
  • transport maximum of glucose
    Æ÷µµ´ç(øãÔ¬ÓØ)À̵¿ÃÖ°íÄ¡.
  • transport medium
    ¼ö¼Û¹èÁö(âÃáêÛÆò¢).
  • transport number
    À̵¿·ü.
  • transport of materials
    ¹°ÁúÀ̵¿(Úªòõì¹ÔÑ).
  • transport oxygen
    »ê¼Ò¿î¹Ý(ß«áÈê¡Úæ).
  • transport phenomenon
    ¹°ÁúÀ̵¿Çö»ó (¡­úÞßÚ).
  • transport system
    Àü´Þ°è
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Nucleus of ansa lenticularis
    ·»Áî°í¸®ÇÙ
    [¿¾ ¿ë¾î] ·»ÁîÇÙ°í¸®ÇÙ
  • Lenticular nucleus
    ·»ÁîÇÙ
    [¿¾ ¿ë¾î] ·»ÁîÇÙ
  • Bacilliform nucleus
    ¸·´ëÇÙ
    [¿¾ ¿ë¾î] °£»óÇÙ
  • Commissural nucleus
    ¸Â±³Â÷ÇÙ
    [¿¾ ¿ë¾î] ±³·ÃÇÙ
  • Dorsal motor nucleus of vagus nerve
    ¹ÌÁֽŰæµîÂÊÇÙ
    [¿¾ ¿ë¾î] ¹ÌÁֽŰæ¹èÃøÇÙ
  • Ventromedial hypothalamic nucleus
    ¹èÂʾÈÂʽûóÇϺÎÇÙ
    [¿¾ ¿ë¾î] º¹³»Ãø½Ã»óÇϺÎÇÙ
  • Segmental nucleus
    ºÐÀýÇÙ
    [¿¾ ¿ë¾î] ºÐÀýÇÙ
  • Cleavage nucleus
    ºÐÇÒÇÙ
    [¿¾ ¿ë¾î] ºÐÇÒÇÙ
  • Nucleus raphe obscurus
    ºÒ¸í¼Ö±âÇÙ
    [¿¾ ¿ë¾î] ºÒ¸íºÀ¼±ÇÙ
  • Interstitial nucleus
    »çÀÌÁúÇÙ
    [¿¾ ¿ë¾î] °£ÁúÇÙ
  • Nucleus intercalatus
    »çÀÌÇÙ
    [¿¾ ¿ë¾î] °³ÀçÇÙ
  • Pontine nucleus of trigeminal nerve
    »ïÂ÷½Å°æ´Ù¸®³úÇÙ
    [¿¾ ¿ë¾î] »ïÂ÷½Å°æ±³ÇÙ
  • Trigemianl motor nucleus
    »ïÂ÷½Å°æ¿îµ¿ÇÙ
    [¿¾ ¿ë¾î] »ïÂ÷½Å°æ¿îµ¿ÇÙ
  • Trigeminal mesencephalic nucleus
    »ïÂ÷½Å°æÁß°£³úÇÙ
    [¿¾ ¿ë¾î] »ïÂ÷½Å°æÁß³ú·ÎÇÙ
  • Spinal nucleus of trigeminal nerve
    »ïÂ÷½Å°æÃ´¼öÇÙ
    [¿¾ ¿ë¾î] »ïÂ÷½Å°æÃ´¼ö·ÎÇÙ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • flexible active site
    °¡º¯(ʦܨ) Ȱ¼º(üÀàõ)ÀÚ¸®
  • surface-active agent
    Ç¥¸éȰ¼ºÁ¦ (øúØüüÀàõð¥)
  • absorption cell
    Èí¼ö¼Ò°ü (ýåâ¥á³Î·)
  • amplifier T cell
    Áõ½Ä T ¼¼Æ÷(ñòãÖ T á¬øà)
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
  • APUD cell
    APUD ¼¼Æ÷(á¬øà)
  • argentaffin cell
    ¾Æ¸£Á¨Å¸ÇÉ ¼¼Æ÷(á¬øà)
  • autosynthetic cell
    ÀÚ°¡ÇÕ¼º¼¼Æ÷ (í»Ê«ùêà÷á¬øà)
  • barrier layer cell
    À庮Ãþ(î¡Ûúöµ) ¼¼Æ÷(á¬øà)
  • B cell
    B ¼¼Æ÷(á¬øà)
  • cell adhesion
    ¼¼Æ÷ºÎÂø(á¬øàÜõó·)
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CTP California Test of Personality; citrate transport protein; clinical terms project; comprehensive tre...
CVTR charcoal viral transport medium
EOT effective oxygen transport
ETC electron transport chain; esophageal tracheal combitude; estimated time of conception
ETP electron transport particle; entire treatment period; ephedrine, theophylline, phenobarbital; eustac...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
AI-CAH Autoimmune chronic active hepatitis
CAH Chronic Active Hepatitis
CAH-B Chronic active hepatitis B
EACs Endocrine active compounds
HAART Highly Active Anti-Retroviral Therapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nucleus gracilis
    ¾ãÀº ´Ù¹ß ÇÙ, ¹Ú¼Ó ÇÙ
    ô¼öÀÇ ¹Ú¼ÓÀÇ »ó´Ü¿¡ ÀÖ´Â ¿¬¼öÀÇ ÇÙÀ¸·Î¼­, ÀÌ ¾È¿¡¼­ ¹Ú¼Ó ¼¶À¯°¡ Á¢ÇÕÇÑ´Ù. ¼¼Æ÷´Â ³»Ãø ¸ð´ë¸¦ °ÅÃļ­ ½Ã»óÀ¸·Î ¹æ»çÇÑ´Ù.
  • nucleus hypothalamicus
    ½Ã»óÇÏ ÇÙ
    µ¿ÀǾî=subthalamic hy
  • nucleus intercalatus
    »çÀÌ ÇÙ, °³Àç ÇÙ
    ¹ÌÁÖ ½Å°æ ¹èÃø ÇÙ°ú ¼³ÇÏ ½Å°æ ÇÙ »çÀÌÀÇ ½Å°æ ¼¼Æ÷±ºÀ¸·Î¼­ ¼³ÇÏ ½Å°æ ÁÖÀ§ÀÇ ÇÙ º¹ÇÕüÀÇ ÀϺθ¦ Çü¼ºÇÑ´Ù.
  • nucleus intermediomedialis
    Áß°£ ³»Ãø ÇÙ
    Áß°£ ¿ÜÃø ÇÙÀÇ ³»Ãø¿¡¼­ Áß°£Áú Á߽ɺο¡ »êÀçÇÏ´Â ¼¼Æ÷·Î ÀÌ·ç¾îÁø ÇÙÀ¸·Î¼­ °æ¼ö¿¡¼­ °¡Àå ÇöÀúÇÏ¸ç ±× ¿¬°áÀÌ Ã´¼ö °íÀ¯ÀÇ °ÍÀ¸·Î »ý°¢µÈ´Ù.
  • nucleus isomer
    ÇÙ À̼ºÃ¼
  • nucleus lemnisci lateralis
    ¿ÜÃø ¼¶À¯¶ì ÇÙ
  • nucleus medialis centralis thalami
    ½Ã»ó Á᫐ ³»Ãø ÇÙ
    ´ëºÎºÐÀÌ ½Ã»óÀÇ ³»Ãø ¼öÆÇ¿¡ ÀÖ´Â ¸í·áÇÑ ÇÙÀ¸·Î¼­ »óºÎÀÇ ³»Ãø ÇÙ°ú ÇϺÎÀÇ Èij»Ãø ÇÙ »çÀÌ¿¡ ÀÖ´Ù. ¼±Á¶Ã¼ ¹× ¿îµ¿ ÇÇÁú°ú º¹ÀâÇÏ°Ô ¿¬°áµÇ¾î ÀÖ´Ù.
  • nucleus medialis thalami
    ½Ã»ó ³»Ãø ÇÙ
    ½Ã»ó ³»Ãø ÇÙ Áß °¡Àå Å« ½Å°æ ÇÙ. ¹®ÃøÀÇ ´ë¼¼Æ÷ºÎ¿Í ¹Ì¿ÜÃøÀÇ ¼Ò¼¼Æ÷ºÎ·Î ÀÌ·ç¾îÁö¸ç, ´Ù¸¥ ½Ã»ó ÇÙÀÇ ´ëºÎºÐ°ú ±¤¹üÀ§ÇÑ ¿¬¶ôÀ» °¡Áø´Ù.
  • nucleus motorius nervi trigemini
    »ïÂ÷ ½Å°æ ¿îµ¿ ÇÙ
    »ïÂ÷ ½Å°æÀÇ ¿îµ¿ ¼¶À¯ÀÇ ±â½Ã ÇÙÀ¸·Î¼­, ÁÖÁö°¢ ÇÙ ¹× À̰÷À¸·Î µé¾î°¡´Â Áö°¢±ÙÀÇ ¹Ù·Î ³»Ãø¿¡ ÀÖ´Â ±³ÀÇ ¹èÃøºÎ¿¡ ÀÖ´Ù.
  • nucleus nervi facialis
    ¾È¸é ½Å°æ ÇÙ
    ¾È¸é ½Å°æ ¿îµ¿ ¼¶À¯ÀÇ ±â½Ã ÇÙÀ¸·Î¼­ ¾È¸é Ç¥Á¤±ÙÀÇ ½Å°æÀ» Áö¹èÇÑ´Ù. ¹éÀº ÇϺα³ÀÇ º¹ ¿ÜÃøºÎ¿¡ ÀÖÀ¸¸ç °Å±â¼­ ³ª¿À´Â ¼¶À¯´Â ¿ÜÀü ½Å°æ ÇÙ ÁÖÀ§¿¡¼­ º¹ÀâÇÑ °í¸®¸¦ Çü¼ºÇÑ´Ù. ÀÌ ¸íĪÀº ¶ÇÇÑ ¿îµ¿ ÇÙ, »óŸ¾× ÇÙ ¹× °í¼Ó ÇÙÀ» ÃÑÄªÇØ¼­ »ç¿ëµÈ´Ù.
  • nucleus nervi hypoglossi
    ¼³ÇÏ ½Å°æ ÇÙ
    ¼³ÇÏ ½Å°æÀÇ ±â½Ã ÇÙÀ¸·Î¼­, ÇϿø®ºê À§Ä¡º¸´Ù ¹Ø¿¡¼­ºÎÅÍ ¿¬¼öÀÇ »óºÎ¿¡ À̸£´Â ³»Ãø À¶±âÀÇ Áß½É È¸¹éÁú¿¡ ³»ÁÖ¸¦ Çü¼ºÇÑ´Ù.
  • nucleus nervi trigemini
    »ïÂ÷ ½Å°æ ÇÙ
    »ïÂ÷ ½Å°æÀÇ ÇÙ º¹ÇÕü·Î¼­, ÁÖ°í ±³ ¹× ¿¬¼ö¿¡ Á¸ÀçÇϳª ÁßÁË ¹× »óºÎ °æ¼ö¿¡µµ Á¸ÀçÇÑ´Ù.
  • nucleus nervi vagi
    ¹ÌÁÖ ½Å°æ ÇÙ
    ¹ÌÁÖ ½Å°æÀÇ ±â½Ã ÇÙ ¹× Á¾¸» ÇÙÀ¸·Î¼­, ¿¬¼ö¿¡ ÀÖÀ¸¸ç ¹èÃø ÇÙ, ÀÇÇÙ ¹× °í¼Ó ÇÙÀ¸·Î ÀÌ·ç¾îÁø´Ù.
  • nucleus nigra
    ÈæÇÙ
  • nucleus of lateral genicutate body
    ¿ÜÃø ¹«¸­ ÇÙ, ¿ÜÃø ½½»óü ÇÙ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
active splint A splint utilizing springs or elastic bands that aids in movements initiated by the patient by controlling the plane and range of motion.
Synonym: active splint, functional splint.
(05 Mar 2000)
active succinate The condensation product of succinic acid and CoA; one of the intermediates of the tricarboxylic acid cycle and a precursor in the synthesis of haem.
Synonym: active succinate, succinyl-CoA.
(05 Mar 2000)
active sulfate 3'-phosphoadenosine 5'-phosphosulfate;an intermediate in the formation of urinary ethereal sulfates, notable for containing a "high energy" sulfate bond; the 3'-OH of adenosine is replaced by -OPO3H2, the 5'-OH by -OP(O2H)-OSO3H.
Synonym: active sulfate.
Acronym: PAPS
(05 Mar 2000)
active treatment A therapeutic substance or course intended to ameliorate the basic disease problem, as opposed to supportive or palliative treatment.
Compare: causal treatment.
(05 Mar 2000)
active vasoconstriction Reduced caliber of a vessel caused by increased tonus in the smooth muscle in its walls.
(05 Mar 2000)
active vasodilation Vasodilation caused by decrease in tonus of smooth muscle in the wall of a vessel.
(05 Mar 2000)
artificial active immunity See: acquired immunity.
(05 Mar 2000)
chronic active hepatitis <pathology> This is a form of continuing liver inflammation that results in liver cell death. Causes include viral infection (hepatitis D, hepatitis B, hepatitis C), autoimmune disease, drug ingestion or metabolic causes. Chronic active hepatitis will lead to hepatic failure and death in a small percentage of these patients.
(27 Sep 1997)
chronic active inflammation The coexistence of chronic inflammation and superimposed acute inflammation.
(05 Mar 2000)
chronic active liver disease Any of several types of hepatitis persisting for more than six months, often progressing to cirrhosis.
Synonym: chronic active liver disease.
(05 Mar 2000)
specific active immunity See: acquired immunity.
(05 Mar 2000)
surface-active Indicating the property of certain agents of altering the physicochemical nature of surfaces and interfaces, bringing about lowering of interfacial tension; they usually possess both lipophilic and hydrophilic groups.
See: surfactant.
(05 Mar 2000)
surface-active agent Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics.
(12 Dec 1998)
surface active compound <biochemistry> Usually, in biological systems, means a detergent like molecule that is amphipathic and that will bind to the plasma membrane or to a surface with which cells come in contact, altering its properties from hydrophobic to hydrophilic or vice versa.
(18 Nov 1997)
immunity, active Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á